 Pyrimidines
"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 0 | 1 | | 1991 | 0 | 2 | 2 | | 1992 | 1 | 0 | 1 | | 1995 | 3 | 0 | 3 | | 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 3 | 1 | 4 | | 1999 | 1 | 1 | 2 | | 2000 | 3 | 1 | 4 | | 2001 | 3 | 3 | 6 | | 2002 | 27 | 9 | 36 | | 2003 | 48 | 14 | 62 | | 2004 | 41 | 18 | 59 | | 2005 | 30 | 14 | 44 | | 2006 | 40 | 18 | 58 | | 2007 | 56 | 40 | 96 | | 2008 | 53 | 30 | 83 | | 2009 | 73 | 25 | 98 | | 2010 | 65 | 27 | 92 | | 2011 | 55 | 32 | 87 | | 2012 | 46 | 29 | 75 | | 2013 | 45 | 32 | 77 | | 2014 | 43 | 21 | 64 | | 2015 | 40 | 20 | 60 | | 2016 | 30 | 18 | 48 | | 2017 | 42 | 23 | 65 | | 2018 | 35 | 25 | 60 | | 2019 | 26 | 20 | 46 | | 2020 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Nguyen JK, Schlichte MJ, Jogi R, Alikhan M, Patel AB. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. Dermatol Online J. 2020 Mar 15; 26(3).
-
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 04; 21(4):531-540.
-
Balasubramaniyan V, Bhat K. Targeting pyrimidine metabolism for glioblastoma therapy. Neuro Oncol. 2020 02 20; 22(2):169-170.
-
Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.
-
Guo L, Li J, Zeng H, Guzman AG, Li T, Lee M, Zhou Y, Goodell MA, Stephan C, Davies PJA, Dawson MA, Sun D, Huang Y. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Nat Commun. 2020 02 06; 11(1):740.
-
Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, Nakada D, Stockwell BR, Gan B. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020 02; 22(2):225-234.
-
Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases? Neuro Oncol. 2019 11 04; 21(11):1344-1345.
-
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 11; 575(7781):217-223.
-
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363.
-
Westin J. Ibrutinib and lenalidomide: when 1+1 = >2. Blood. 2019 09 26; 134(13):996-998.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|